- Home
- TXMD vs CHRO Comparison
TXMD vs CHRO Comparison
Compare TXMD & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- CHRO
- Stock Information
- Founded
- TXMD 2008
- CHRO 2002
- Country
- TXMD United States
- CHRO United States
- Employees
- TXMD N/A
- CHRO N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- TXMD Health Care
- CHRO
- Exchange
- TXMD Nasdaq
- CHRO Nasdaq
- Market Cap
- TXMD 12.8M
- CHRO 11.3M
- IPO Year
- TXMD N/A
- CHRO 2024
- Fundamental
- Price
- TXMD $1.30
- CHRO $1.68
- Analyst Decision
- TXMD
- CHRO Strong Buy
- Analyst Count
- TXMD 0
- CHRO 1
- Target Price
- TXMD N/A
- CHRO N/A
- AVG Volume (30 Days)
- TXMD 738.0K
- CHRO 104.9K
- Earning Date
- TXMD 03-28-2025
- CHRO 03-04-2025
- Dividend Yield
- TXMD N/A
- CHRO N/A
- EPS Growth
- TXMD N/A
- CHRO N/A
- EPS
- TXMD N/A
- CHRO N/A
- Revenue
- TXMD $1,596,000.00
- CHRO N/A
- Revenue This Year
- TXMD $605.07
- CHRO N/A
- Revenue Next Year
- TXMD $1.11
- CHRO N/A
- P/E Ratio
- TXMD N/A
- CHRO N/A
- Revenue Growth
- TXMD N/A
- CHRO N/A
- 52 Week Low
- TXMD $0.70
- CHRO $0.45
- 52 Week High
- TXMD $2.75
- CHRO $4.84
- Technical
- Relative Strength Index (RSI)
- TXMD 68.51
- CHRO 50.49
- Support Level
- TXMD $0.95
- CHRO $1.59
- Resistance Level
- TXMD $1.08
- CHRO $1.99
- Average True Range (ATR)
- TXMD 0.09
- CHRO 0.29
- MACD
- TXMD 0.02
- CHRO -0.06
- Stochastic Oscillator
- TXMD 49.30
- CHRO 41.44
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.